264 related articles for article (PubMed ID: 26692253)
1. Interleukin-1 antagonism moderates the inflammatory state associated with Type 1 diabetes during clinical trials conducted at disease onset.
Cabrera SM; Wang X; Chen YG; Jia S; Kaldunski ML; Greenbaum CJ; ; Mandrup-Poulsen T; ; Hessner MJ
Eur J Immunol; 2016 Apr; 46(4):1030-46. PubMed ID: 26692253
[TBL] [Abstract][Full Text] [Related]
2. Interleukin-1 antagonism in type 1 diabetes of recent onset: two multicentre, randomised, double-blind, placebo-controlled trials.
Moran A; Bundy B; Becker DJ; DiMeglio LA; Gitelman SE; Goland R; Greenbaum CJ; Herold KC; Marks JB; Raskin P; Sanda S; Schatz D; Wherrett DK; Wilson DM; Krischer JP; Skyler JS; ; Pickersgill L; de Koning E; Ziegler AG; Böehm B; Badenhoop K; Schloot N; Bak JF; Pozzilli P; Mauricio D; Donath MY; Castaño L; Wägner A; Lervang HH; Perrild H; Mandrup-Poulsen T;
Lancet; 2013 Jun; 381(9881):1905-15. PubMed ID: 23562090
[TBL] [Abstract][Full Text] [Related]
3. Treating inflammation by blocking interleukin-1 in humans.
Dinarello CA; van der Meer JW
Semin Immunol; 2013 Dec; 25(6):469-84. PubMed ID: 24275598
[TBL] [Abstract][Full Text] [Related]
4. Anti-Inflammatory Therapy With Canakinumab for the Prevention and Management of Diabetes.
Everett BM; Donath MY; Pradhan AD; Thuren T; Pais P; Nicolau JC; Glynn RJ; Libby P; Ridker PM
J Am Coll Cardiol; 2018 May; 71(21):2392-2401. PubMed ID: 29544870
[TBL] [Abstract][Full Text] [Related]
5. A Preclinical Consortium Approach for Assessing the Efficacy of Combined Anti-CD3 Plus IL-1 Blockade in Reversing New-Onset Autoimmune Diabetes in NOD Mice.
Gill RG; Pagni PP; Kupfer T; Wasserfall CH; Deng S; Posgai A; Manenkova Y; Bel Hani A; Straub L; Bernstein P; Atkinson MA; Herold KC; von Herrath M; Staeva T; Ehlers MR; Nepom GT
Diabetes; 2016 May; 65(5):1310-6. PubMed ID: 26718498
[TBL] [Abstract][Full Text] [Related]
6. Preliminary studies related to anti-interleukin-1β therapy in children with newly diagnosed type 1 diabetes.
Sumpter KM; Adhikari S; Grishman EK; White PC
Pediatr Diabetes; 2011 Nov; 12(7):656-67. PubMed ID: 21518168
[TBL] [Abstract][Full Text] [Related]
7. Impact of interleukin-1β antibody (canakinumab) on glycaemic indicators in patients with type 2 diabetes mellitus: results of secondary endpoints from a randomized, placebo-controlled trial.
Hensen J; Howard CP; Walter V; Thuren T
Diabetes Metab; 2013 Dec; 39(6):524-31. PubMed ID: 24075453
[TBL] [Abstract][Full Text] [Related]
8. Anti-IL-1 molecules: new comers and new indications.
Moltó A; Olivé A
Joint Bone Spine; 2010 Mar; 77(2):102-7. PubMed ID: 20045371
[TBL] [Abstract][Full Text] [Related]
9. Cerebrospinal Fluid Cytokines Correlate With Aseptic Meningitis and Blood-Brain Barrier Function in Neonatal-Onset Multisystem Inflammatory Disease: Central Nervous System Biomarkers in Neonatal-Onset Multisystem Inflammatory Disease Correlate With Central Nervous System Inflammation.
Rodriguez-Smith J; Lin YC; Tsai WL; Kim H; Montealegre-Sanchez G; Chapelle D; Huang Y; Sibley CH; Gadina M; Wesley R; Bielekova B; Goldbach-Mansky R
Arthritis Rheumatol; 2017 Jun; 69(6):1325-1336. PubMed ID: 28118536
[TBL] [Abstract][Full Text] [Related]
10. MRP8 and MRP14, phagocyte-specific danger signals, are sensitive biomarkers of disease activity in cryopyrin-associated periodic syndromes.
Wittkowski H; Kuemmerle-Deschner JB; Austermann J; Holzinger D; Goldbach-Mansky R; Gramlich K; Lohse P; Jung T; Roth J; Benseler SM; Foell D
Ann Rheum Dis; 2011 Dec; 70(12):2075-2081. PubMed ID: 21908452
[TBL] [Abstract][Full Text] [Related]
11. Residual inflammatory risk associated with interleukin-18 and interleukin-6 after successful interleukin-1β inhibition with canakinumab: further rationale for the development of targeted anti-cytokine therapies for the treatment of atherothrombosis.
Ridker PM; MacFadyen JG; Thuren T; Libby P
Eur Heart J; 2020 Jun; 41(23):2153-2163. PubMed ID: 31504417
[TBL] [Abstract][Full Text] [Related]
12. Canakinumab: a human anti-IL-1β monoclonal antibody for the treatment of cryopyrin-associated periodic syndromes.
Church LD; McDermott MF
Expert Rev Clin Immunol; 2010 Nov; 6(6):831-41. PubMed ID: 20979548
[TBL] [Abstract][Full Text] [Related]
13. Effect of anti-IL-1β antibody (canakinumab) on insulin secretion rates in impaired glucose tolerance or type 2 diabetes: results of a randomized, placebo-controlled trial.
Rissanen A; Howard CP; Botha J; Thuren T;
Diabetes Obes Metab; 2012 Dec; 14(12):1088-96. PubMed ID: 22726220
[TBL] [Abstract][Full Text] [Related]
14. Failure of anti Interleukin-1 β monoclonal antibody in the treatment of recurrent pericarditis in two children.
Signa S; D'Alessandro M; Consolini R; Miniaci A; Bustaffa M; Longo C; Tosca MA; Bizzi M; Caorsi R; Mendonça LO; Pession A; Ravelli A; Gattorno M
Pediatr Rheumatol Online J; 2020 Jun; 18(1):51. PubMed ID: 32546242
[TBL] [Abstract][Full Text] [Related]
15. Sustained efficacy of the monoclonal anti-interleukin-1 beta antibody canakinumab in a 9-month trial in Schnitzler's syndrome.
de Koning HD; Schalkwijk J; van der Ven-Jongekrijg J; Stoffels M; van der Meer JW; Simon A
Ann Rheum Dis; 2013 Oct; 72(10):1634-8. PubMed ID: 23087179
[TBL] [Abstract][Full Text] [Related]
16. Treatment of Muckle-Wells syndrome: analysis of two IL-1-blocking regimens.
Kuemmerle-Deschner JB; Wittkowski H; Tyrrell PN; Koetter I; Lohse P; Ummenhofer K; Reess F; Hansmann S; Koitschev A; Deuter C; Bialkowski A; Foell D; Benseler SM
Arthritis Res Ther; 2013; 15(3):R64. PubMed ID: 23718630
[TBL] [Abstract][Full Text] [Related]
17. Synergistic reversal of type 1 diabetes in NOD mice with anti-CD3 and interleukin-1 blockade: evidence of improved immune regulation.
Ablamunits V; Henegariu O; Hansen JB; Opare-Addo L; Preston-Hurlburt P; Santamaria P; Mandrup-Poulsen T; Herold KC
Diabetes; 2012 Jan; 61(1):145-54. PubMed ID: 22043003
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetic and pharmacodynamic properties of canakinumab, a human anti-interleukin-1β monoclonal antibody.
Chakraborty A; Tannenbaum S; Rordorf C; Lowe PJ; Floch D; Gram H; Roy S
Clin Pharmacokinet; 2012 Jun; 51(6):e1-18. PubMed ID: 22550964
[TBL] [Abstract][Full Text] [Related]
19. Successful response in a case of severe pustular psoriasis after interleukin-1β inhibition.
Skendros P; Papagoras C; Lefaki I; Giatromanolaki A; Kotsianidis I; Speletas M; Bocly V; Theodorou I; Dalla V; Ritis K
Br J Dermatol; 2017 Jan; 176(1):212-215. PubMed ID: 27105586
[TBL] [Abstract][Full Text] [Related]
20. The anti-interleukin-1 in type 1 diabetes action trial--background and rationale.
Pickersgill LM; Mandrup-Poulsen TR
Diabetes Metab Res Rev; 2009 May; 25(4):321-4. PubMed ID: 19405081
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
